BIIB logo

Biogen Inc.

BIIB
Healthcare|Drug Manufacturers - General|US
$248.35
+4.42 (+1.81%)
DCF Value
$517.66
Graham Number
$82.35
Cash / Share
$8.82

About

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.

Stock Price

+58.4%(1Y)
1M
+13.7%
3M
+19.4%
6M
+28.4%
YTD
+41.1%
1Y
+58.9%
3Y
+7.2%
5Y
-8.9%

Pipeline Summary

515 total trials
147
Phase 1
118
Phase 2
92
Phase 3
55
Phase 4
Unknown: 9Withdrawn: 18Active: 16Completed: 356Terminated: 82Recruiting: 25No Longer Available: 2Not Yet Recruiting: 3By Invitation: 3Approved: 1

Active Trials (41)

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
NCT04468659Preclinical Alzheimer's Disease
Phase 3Active
Enrollment: 1,400 participants
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455Early Alzheimer's Disease
Phase 3Active
Enrollment: 1,906 participants
The Myelin Disorders Biorepository Project
NCT03047369Leukodystrophy
Recruiting
Enrollment: 12,000 participants
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
NCT05866419Spinal Muscular Atrophy
N/ARecruiting
Enrollment: 90 participants
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
NCT06555419Muscular Atrophy, Spinal
Phase 1Recruiting
Enrollment: 78 participants

BioScore

6/10
Watchlist

Key Facts

Market Cap$36.71B
Employees7,500 (-1% YoY)
CEOChristopher A. Viehbacher
IPO DateSep 17, 1991
Beta0.17
52-Week Range$153.77 – $258.78
Avg Volume1,146,246
ExchangeNASDAQ
Websitebiogen.com

Ownership

Float99.2%
Shares Outstanding147.8M

Recent Insider Trades

Grogan JaneOPTION EX.
Oct 30, 2026695 shares
Grogan JaneTAX W/H
Oct 30, 2026345 shares @ $253.62
Grogan JaneOPTION EX.
Oct 30, 2026695 shares
Godbout SeanOPTION EX.
Oct 2, 202627 shares
Godbout SeanTAX W/H
Oct 2, 20268 shares @ $219.88

Peers

ALNYAlnylam Pharmaceuticals, Inc.
$20.89B
AMGNAmgen Inc.
$248.92B
AZNAstraZeneca PLC
$289.14B
IONSIonis Pharmaceuticals, Inc.
$6.55B
LLYEli Lilly and Company
$1273.77B
PFEPfizer Inc.
$167.51B
PTCTPTC Therapeutics, Inc.
$5.47B
REGNRegeneron Pharmaceuticals, Inc.
$93.54B
Data last updated: Nov 9, 2026, 03:59 AM